Background
==========

Breast cancer is the most common cancer in American women, with over 40,000 annual deaths and nearly 200,000 estimated new cases in 2009 \[[@B1]\]. Given the high prevalence of breast cancer and associated physical, social, and psychological detriments \[[@B2]\], reducing cancer incidence through modifiable risk factors such as nutrition is a high public health priority. Estimates suggest that cancer incidence could be reduced by \~1/3 through modifications in diet, including changes in total energy intake and diet content of fat, protein or carbohydrate \[[@B3]\]. With increased attention on higher protein, low carbohydrate diets for weight management, secondary effects of these diets on tumor development are important to evaluate.

Some studies report that dietary protein, and particularly consumption of animal protein, is linked to increased risk of breast cancer \[[@B4],[@B5]\]. However, recent large-scale evaluations have failed to identify intakes of meat, eggs, or dairy products as risk factors \[[@B6]\]. Conversely, epidemiological studies have reported protective effects of dietary protein on breast cancer incidence \[[@B7]\] and mortality \[[@B8]\]. A recent case-controlled study suggests that a dietary pattern including the highest relative levels of animal protein is inversely associated with breast cancer risk \[[@B9]\].

Evidence is now accumulating that dietary carbohydrates, glycemic load, and hyperinsulinemia are associated with increased cancer risk \[[@B10],[@B11]\] and mortality \[[@B12]\]. Higher levels of circulating and post-prandial insulin have been reported to enhance cellular proliferation and tumor development \[[@B13]\] through upregulation of the PI3K/Akt signal pathway which is implicated in breast cancer promotion and tumorigenesis \[[@B14]\]. Furthermore, insulin stimulates the ovaries to produce androgens \[[@B15]\], which have been linked to increased breast cancer risk \[[@B16]\]. To our knowledge, no studies have attempted to compare the effects of dietary protein versus carbohydrates in an experimental model of breast cancer.

We have previously demonstrated that feeding rats diets with increased protein and reduced carbohydrates enhances muscle insulin signaling and glucose uptake, attenuates post-prandial hyperinsulinemia, and stimulates skeletal muscle protein synthesis \[[@B17],[@B18]\]. Our experimental model uses a meal-feeding protocol with three discrete meals each day to mimic human eating patterns and allow for isolation of post-prandial meal responses. This study examined the effects of feeding diets differing in ratios of carbohydrate/protein, but within the Dietary Reference Intake (DRI) acceptable macronutrient distribution range, on tumor incidence, size, and development, in a chemically-induced model of breast cancer. We hypothesized that a diet with a reduced carbohydrate:protein ratio would have a favorable impact on breast cancer development by tempering post-prandial insulin response.

Methods
=======

Experimental Model
------------------

Female 45 d old Sprague-Dawley rats (n = 74; Harlan-Teklad, Indianapolis, IN) with a mean body weight of 135 ± 4.8 g were housed individually in stainless steel wire-bottomed cages and maintained at 24°C with 12 h reverse light cycle (light: 1900-0700 h) and free access to water. Rats were trained to consume three meals each day using a modified AIN-93G diet \[[@B19]\] (60% of energy from carbohydrate, 15% protein, and 25% fat; LPHC) as the baseline control. The meal pattern consisted of a 3 g breakfast meal (20% of total energy) consumed between 0700-0720 h, followed by free access to food between 1300-1400 h (\~40% total energy) and 1800-1900 h (\~40% total energy). At 52 d of age, animals were randomly assigned to consume either the baseline low protein high carbohydrate diet (LPHC; n = 37) or a high protein moderate carbohydrate diet (40% carbohydrate, 35% protein, and 25% fat; HPMC; n = 37) (Table [1](#T1){ref-type="table"}). Both diet treatments were isoenergetic. Tumors were induced in all animals at 52 d of age by a single intraperitoneal dose of N-methyl-N-nitrosourea (MNU) at 50 mg/kg body weight in 1 ml of 0.9% NaCl \[[@B20]\]. Rats were weighed and food intake measured each week. The animal protocol was approved by the University of Illinois Institutional Animal Care and Use Committee.

###### 

Diet Composition for Treatment Groups

  Diet Component        LPHC     HPMC
  --------------------- -------- --------
  Corn Starch           396.69   264.46
  Sucrose               99.96    66.64
  Maltodextrin          132.02   88.01
  Casein                154.85   361.27
  Soybean Oil           116.24   116.24
  t-Butylhydroquinone   0.014    0.014
  Choline               2.5      2.5
  AIN93G Minerals       35       35
  AIN93G Vitamins       10       10
  Cellulose             50       50
  Cystine               2.36     2.36

Grams per kg diet. LPHC and HPMC represent low protein and high protein diet groups, respectively.

Measurements
------------

At 3 wk post-MNU treatment, rats were randomly selected from LPHC (n = 12) and HPMC (n = 12) groups and evaluated for metabolic changes associated with diet treatments prior to tumor appearance. Rats were euthanized either after overnight food deprivation (fasted) or 90 min following consumption of a 3 g breakfast meal. Trunk blood was collected in K~3~EDTA vacutainers (BD, Franklin Lakes, NJ), placed on ice, and subsequently centrifuged at 1500 × G at 4°C for 20 min. Plasma was decanted and stored at -80°C for further analysis. Soleus and gastrocnemius muscles of the left leg were rapidly excised and frozen in liquid nitrogen, while the soleus and gastrocnemius of the right leg were dissected and weighed. Likewise, the left retroperitoneal fat pad was excised and frozen and the right retroperitoneal fat pad dissected and weighed. Liver was excised, weighed, and frozen. The 3 wk time point was intended to capture metabolic differences that could affect tumor promotion, while avoiding confounding pathology associated with tumor development.

At 10 wk post-induction, rats from LPHC (n = 12) and HPMC (n = 12) were measured for body fat using dual-energy X-ray absorptiometery (DXA) (Hologic, Inc., Bedford, MA). To isolate diet effects on body composition, only rats without palpable tumors were scanned. Rats were sedated with medetomidine hydrochloride (Orion, Espoo, Finland) at 0.3 mg/kg body weight 10 min prior to scanning, and were revived with atipamezole (Orion, Espoo, Finland) at 0.15 mg/kg body weight following the scan. All rats (LPHC: n = 25; HPMC: n = 25) were euthanized in a similar manner 3-4 d after DXA scanning and blood, soleus and gastrocnemius muscles, adipose, and liver were collected and weighed as previously described. Mammary tumors were rapidly excised, weighed, rinsed in saline, and a portion was fixed for 24 hr in 10% neutral buffered formalin for histological analysis. Fixed tumors were stored in 75% ethanol, then subsequently dehydrated and imbedded in paraffin. Imbedded tumors were then sectioned at 2-4 μM and stained with hematoxylin and eosin. Tumor sections were graded histologically on the following semi-quantitative scale: 0 - low grade adenocarcinoma, 1 - high grade adenocarcinoma, 2 - mild mammary hyperplasia, 3 - marked mammary hyperplasia.

Carcinogenesis Parameters
-------------------------

Animals were monitored for mammary tumor appearance beginning at 5 wk post-induction through the remainder of the study and after animal euthanasia. Rats were palpated for mammary tumors 2 times/wk. When a tumor was detected, the date and tumor location were recorded. Tumor incidence and latency to tumor appearance were determined qualitatively by palpation. Tumor dimensions of length and width were measured orthogonally by caliper. Tumor surface area was calculated by the following formula: 4π × (length/2) × (width/2). Following euthanasia, all tumors were excised and weighed.

Metabolic Analyses
------------------

Plasma glucose was measured by glucose oxidase assay (Thermo, Waltham, MA). Plasma insulin was measured by commercial RIA kit (Millipore, Billerica, MA). Plasma IGF-I was measured by RIA after dissociation from IGFBP by Sephadex G-50 chromatography in 0.2 M formic acid. Eluant containing the free IGF was collected and lyophilized (Labconco Freeze Dry Systems, Kansas City, MO). IGF-I concentrations were measured using \[^125^I\]-IGF-I as a competitive radioligand and a polyclonal anti-human antibody (National Hormone and Pituitary Program, NIDDK, Torrance, CA). Bound radioactivity was measured using a gamma counter (Packard Instruments, Meriden, CT) and concentrations were determined relative to a standard curve prepared with recombinant human IGF-I \[[@B21]\].

Statistical Analysis
--------------------

Data are expressed as mean ± SEM. Plasma glucose, insulin, and IGF-I were analyzed using 2-way ANOVA and between-diet differences were evaluated at each time point. Tumor incidence and time of appearance were evaluated using linear regression analysis. Histological classification of excised tumors was analyzed with a Mann-Whitney U test. All other carcinogenesis parameters, as well as body weight and food intake were analyzed by a Student\'s *t*-test. The level of significance was set at *P*\< 0.05. All analyses were performed using SPSS Version 15.0 (Chicago, IL).

Results
=======

Animal Weight Gain, Food Intake, and Body Composition
-----------------------------------------------------

Body weights of HPMC and LPHC groups were not different at baseline (Figure [1](#F1){ref-type="fig"}). At 3 wk, there were no differences between groups in body weight or weights of gastrocnemius, soleus, or retroperitoneal fat pad (Table [2](#T2){ref-type="table"}). Body weight was greater in the HPMC group at wks 3, 5-7, and 9-10 (*P*\< 0.05) (Figure [1](#F1){ref-type="fig"}). There were no differences in food intake between groups at any time during the study. At 10 wk, there were no differences in gastrocnemius or soleus weights between diet groups (Table [2](#T2){ref-type="table"}) or in % body fat measured by DXA. However, retroperitoneal fat and liver were heavier in the HPMC group.

![**Body Weights; Values represent Means ± SEM**. \* indicates significant difference (P \> 0.05).](1743-7075-7-1-1){#F1}

###### 

Body Composition Measures

                                     LPHC            HPMC            *P*value
  -------------------------- ------- --------------- --------------- ----------
  Gastrocnemius weight (g)   3 wk    1.32 ± 0.03     1.32 ± 0.05     0.939
                                                                     
                             10 wk   1.54 ± 0.02     1.57 ± 0.03     0.398
                                                                     
  Soleus weight (g)          3 wk    0.245 ± 0.006   0.237 ± 0.009   0.472
                                                                     
                             10 wk   0.299 ± 0.007   0.309 ± 0.006   0.281
                                                                     
  Adipose weight (g)         3 wk    0.374 ± 0.056   0.358 ± 0.055   0.844
                                                                     
                             10 wk   0.443 ± 0.037   0.585 ± 0.047   0.021
                                                                     
  Liver weight (g)           3 wk    \-              \-              \-
                                                                     
                             10 wk   5.60 ± 0.13     6.04 ± 0.11     0.012
                                                                     
  \% Body fat                10 wk   10.8 ± 0.6      11.2 ± 0.7      0.588

Values represent Mean ± SEM, n = 6 for each fasted and fed group.

Serum Glucose, Insulin, & IGF-I Concentrations
----------------------------------------------

Serum glucose was not different between groups at 3 or 10 wk (Table [3](#T3){ref-type="table"}) in either fasted or post-prandial blood samples. At 3 wk, fasting insulin tended to be higher in the HPMC group (*P*= 0.09), while the meal response of serum insulin was greater in the LPHC group compared to HPMC group (+136.4 ± 33.1 pmol/L vs. +38.1 ± 23.4 pmol/L, respectively; *P*= 0.035). At 10 wk, post-prandial serum insulin was elevated in both LPHC and HPMC groups compared to fasted animals. Serum IGF-I was not significantly modified by diet or meal-feeding at 3 wk. At 10 wk there was a trend for serum IGF-I to be increased post-prandially in the HPMC group (*P*= 0.055).

###### 

Plasma Metabolic Measurements

  ----------------------------------------------------------------------------------------------------
                                    Fasted         Fed            Time Effect\   Time × Diet Effect\
                                                                  *P*Value       *P*Value
  ------------------ ------- ------ -------------- -------------- -------------- ---------------------
  Glucose (mmol/L)   3 wk    LPHC   6.86 ± 0.50    6.74 ± 0.44    0.854          0.841

                             HPMC   7.16 ± 0.48    6.84 ± 0.47    0.642          

                                                                                 

                     10 wk   LPHC   6.73 ± 0.18    6.54 ± 0.27    0.565          0.656

                             HPMC   6.70 ± 0.27    6.74 ± 0.31    0.917          

                                                                                 

  Insulin (pmol/L)   3 wk    LPHC   77.4 ± 11.6    213.8 ± 33.1   0.003          0.075

                             HPMC   125.1 ± 19.8   163.2 ± 23.4   0.350          

                                                                                 

                     10 wk   LPHC   86.2 ± 10.4    194.4 ± 29.7   0.002          0.520

                             HPMC   77.5 ± 5.8     220.2 ± 37.6   0.003          

                                                                                 

  IGF-I (μg/L)       3 wk    LPHC   240 ± 24       272 ± 26       0.396          0.564

                             HPMC   274 ± 10       268 ± 32       0.917          

                                                                                 

                     10 wk   LPHC   205 ± 30       211 ± 17       0.851          0.221

                             HPMC   237 ± 17       299 ± 23       0.055          
  ----------------------------------------------------------------------------------------------------

Values represent Mean ± SEM, n = 6 for each fasted and fed group

Carcinogenesis Parameters
-------------------------

At 3 wk post-induction, no animals had palpable tumors and no tumors were found during dissection. Initial palpable tumors were detected at 51 d in the LPHC group and 55 d in the HPMC group. Surface area of palpable tumors was not different between treatments at any time point. The rate of tumor incidence was higher in the LPHC group with relative slopes of tumor incidence of 18.2 ± 1.3%/wk and 12.9 ± 1.4%/wk (*P*\< 0.05) for the LPHC and HPMC groups, respectively (Figure [2](#F2){ref-type="fig"}). Other characteristics of tumor incidence, tumor latency (average time to first tumor development), and cumulative tumor mass at 10 wk, were not different between treatments (Table [4](#T4){ref-type="table"}). All excised tumors were confirmed histologically to be mammary ductal carcinomas, and there were no differences between groups in the grade of the carcinomas.

![**Tumor Incidence; Comparison of slopes of linear regression (P = 0.019); LPHC: y = 18.10x - 119.3, r^2^= 0.968; HPMC: y = 12.95x - 87.86, r^2^= 0.937**.](1743-7075-7-1-2){#F2}
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Carcinogenesis Parameters

                                       LPHC          HPMC          *P*value
  ------------------------------------ ------------- ------------- ----------
  Tumor Incidence at 10 wk             0.56          0.4           \> 0.05
  Tumor Latency (wk)                   8.36 ± 0.21   8.60 ± 0.26   \> 0.05
  Cumulative Tumor Mass (g)            2.22 ± 0.67   2.51 ± 1.40   \> 0.05
  Rate of Tumor Incidence (% per wk)   18.2 ± 1.3    12.9 ± 1.4    0.019

Values represent Means ± SEM.

Discussion
==========

The objective of this study was to identify potential effects of manipulating the dietary carbohydrate:protein ratio on the promotion of MNU-induced breast cancer tumors. A major finding of our study is that a HPMC diet with an reduced carbohydrate:protein ratio significantly reduced the rate of incidence of palpable mammary tumors. Although tumor latency was not different between groups, once palpable tumors began to appear, the rate of tumor appearance proceeded more rapidly in the LPHC group. This suggests that either reduced dietary carbohydrate or elevated dietary protein (or both), can attenuate the early development of mammary tumors. In agreement with our previous study \[[@B17]\], post-prandial insulin at 3 wk was elevated in the LPHC group and not in the HPMC group. Thus, animals in the LPHC group were likely exposed to higher, repeated elevations in serum insulin following each discrete meal during the period leading to the emergence of palpable mammary tumors. Post-prandial insulin at 10 wk was elevated in both groups, although host metabolism was likely confounded by tumor pathology, and this change does not necessarily diminish the early effect of post-prandial insulin on tumor promotion.

Nearly two decades ago, hyperinsulinemia was identified as a significant risk factor for breast cancer, independent of body composition or adiposity \[[@B22]\]. Cohort studies have found that women surgically treated for breast cancer with high fasted insulin levels had substantially increased risk for reoccurrence and death \[[@B23]\] and that the highest tertile of fasted insulin levels was associated with a 2-fold increase in post-menopausal breast cancer risk \[[@B24],[@B25]\]. Most recently, the presence of metabolic syndrome was reported to be associated with breast cancer risk \[[@B26]\], and insulin resistance and post-prandial hyperinsulinemia are central features of metabolic syndrome \[[@B27]\], leading to suggestions that metabolic syndrome may serve as a prognostic factor for breast cancer \[[@B28]\]. With respect to dietary factors, a positive association between high glycemic index/load and breast cancer risk has been identified \[[@B29],[@B30]\]. High total carbohydrate intake \[[@B31]\] and sucrose intake have been associated with unfavorable outcomes for breast cancer.

One of the mechanisms by which insulin has been proposed to increase breast cancer risk is via IGF-I. Elevated insulin can increase serum free IGF-I concentrations \[[@B32]\]. Overexpression of IGF-I in mammary epithelium *in vivo*leads to hyperplasia, spontaneous tumorogenesis, and enhanced susceptibility to chemical carcinogens \[[@B33]\], and circulating IGF-I appears to be important for the onset and subsequent development of mammary tumorigenesis in *in vivo*experiments \[[@B34],[@B35]\]. In the present study, the elevated post-prandial insulin observed in the LPHC group was not associated with increased serum IGF-I concentrations.

Clinically, the effect of IGF-I on breast cancer remains equivocal. Elevated serum IGF-I concentrations appear to increase risk of pre-, but not post-menopausal breast cancer, while higher blood glucose levels were associated with increased risk for developing post-menopausal breast cancer \[[@B36]\]. However, a case control study identified a weak association for IGF-I with breast cancer in women under the age of fifty \[[@B37]\]. Most recently, the Women\'s Health Initiative study found a strong association between fasting insulin levels and breast cancer in post-menopausal women, but no association of free IGF-I \[[@B38]\].

IGF-I bioactivity is modulated by IGF binding proteins (IGFBP), which can block IGF-I from binding to its receptor. At least 75% of circulating IGF-I is bound to IGFBP-3 \[[@B39]\], though IGFBP-3 levels remain fairly constant within individuals \[[@B40]\]. IGFBP-1 and IGFBP-2 levels are inversely associated with insulin levels \[[@B41]\], which suggests that chronic hyperinsulinemia could depress binding protein interaction and thus increase free IGF-I. Serum IGF-I levels have also been shown to relate to protein intake \[[@B42]\]. In the present study at 10 wk, there was a trend for post-prandial IGF-I to be higher (p = 0.055) in the HPMC group. Despite the elevation of IGF-I in the HPMC group, the rate of tumor incidence was significantly lower.

Consistent with our findings, early animal experiments investigating the influence of dietary protein on breast cancer found that feeding a higher protein diet prior to administration of a carcinogen resulted in a reduction of tumor prevalence \[[@B43]\], suggesting a protective effect of protein during the initiation phase. Additionally, increased dietary protein fed after tumor induction had no independent effect on the promotion phase of carcinogenesis \[[@B44]\]. In contrast to the findings of the present study, Hawrylewicz et al. found higher dietary protein (33% vs. 15%) increased the number of tumors and tumor weight in MNU-induced rats, despite no difference in tumor incidence or latency \[[@B45]\]. However, this study differed substantially from the current study in that the rats were exposed in utero from dams fed the test diets and then consumed the same test diets *ad libitum*after weaning.

A further consideration is that elevated dietary protein was accomplished at the expense of dietary carbohydrate, and since tumors are obligate glucose consumers, HPMC may have been less energetically favorable to neoplastic tissues. Similarly, a ketogenic diet (80% medium chain triglycerides) fed to mice with implanted colon adenocarcinomas reduced tumor weight, while the inclusion of hydroxybutyrate in drinking water counteracted the stimulation of tumor growth by insulin infusion \[[@B46]\]. However, fasted glucose was not different between groups at either 3 or 10 wks, and in reflecting current dietary guidelines, the HPMC diet was not low enough in carbohydrate to induce ketogenesis.

A limitation of the current study is its relatively short length. At 10 wks, tumor incidence had only reached 40% in the HPMC group. Due to the labor-intensive nature of the meal-feeding protocol, this study was designed for 10 wk, with a goal of both groups exceeding 50% tumor incidence. However, within the short period of time, the study still achieved divergent rates of tumor appearance between diet groups.

Conclusion
==========

In total, the present study provides evidence that reducing the dietary carbohydrate:protein ratio attenuates the progression of mammary tumors, and this finding is consistent with reduced post-prandial insulin release potentially diminishing the proliferative environment required for breast cancer tumors to progress. These results warrant additional investigation into the potentially protective effect that elevated dietary protein and reduced carbohydrate may have on breast cancer development.
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